1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus Infections - Pipeline Review, H2 2020, provides an overview of the Cytomegalovirus Infections (Infectious Disease) pipeline landscape.
Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cytomegalovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cytomegalovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 7, 19, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 10, 10, 2, 6 and 3 molecules, respectively.
Cytomegalovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cytomegalovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cytomegalovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cytomegalovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cytomegalovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionCytomegalovirus Infections - Overview
Cytomegalovirus Infections - Therapeutics Development
Cytomegalovirus Infections - Therapeutics Assessment
Cytomegalovirus Infections - Companies Involved in Therapeutics Development
Cytomegalovirus Infections - Drug Profiles
Cytomegalovirus Infections - Dormant Projects
Cytomegalovirus Infections - Discontinued Products
Cytomegalovirus Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Abhelix LLC, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by AlloVir Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Artemis Therapeutics Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Holdings Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by China Immunotech Co Ltd, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Evrys Bio, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Helocyte Biosciences Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Pharma Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Huinuo Biomedical Technology Co Ltd, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by iCELL Biotechnology Co Ltd, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Karyopharm Therapeutics Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Memo Therapeutics AG, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Inc, H2 2020
- Cytomegalovirus (HHV-5) Infections - Pipeline by Nobelpharma Co Ltd, H2 2020
- Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2020
- Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abhelix LLC
- AlloVir Inc
- Artemis Therapeutics Inc
- Atara Biotherapeutics Inc
- Biotest AG
- Chengdu Rongsheng Pharmaceutical Co Ltd
- China Biologic Products Holdings Inc
- China Immunotech Co Ltd
- Evrys Bio
- Fate Therapeutics Inc
- GlaxoSmithKline Plc
- Helocyte Biosciences Inc
- Hookipa Pharma Inc
- Huinuo Biomedical Technology Co Ltd
- iCELL Biotechnology Co Ltd
- Karyopharm Therapeutics Inc
- Memo Therapeutics AG
- Merck & Co Inc
- Microbiotix Inc
- Moderna Inc
- Nobelpharma Co Ltd
- Okogen Inc
- Orgenesis Inc
- Phoenix Biotechnology Inc
- Prosit Sole Biotechnology (Beijing) Co Ltd
- Provention Bio Inc
- Savoy Pharmaceuticals Inc
- SL VaxiGen Inc
- SpyBiotech Ltd
- Stadius Biopharma LLC
- Synklino ApS
- Takeda Pharmaceutical Co Ltd
- Themis Bioscience GmbH
- Trellis Bioscience Inc
- VBI Vaccines Inc
- Vichem Chemie Research Ltd
- Viramatix Sdn Bhd
- Zhuhai Trinomab Biotechnology Co Ltd
